(E)-3-(4-bromophenyl)-2-phenylacrylic acid | 92439-75-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-3-(4-bromophenyl)-2-phenylacrylic acid
• 英文别名: p-Brom-α-phenyl-trans-zimtsaeure；4-Brom-α-phenyl-trans-zimtsaeure；(E)-3-(4-bromophenyl)-2-phenylprop-2-enoic acid
• CAS: 92439-75-3
• 化学式: C₁₅H₁₁BrO₂
• 分子量: 303.155
• InChiKey: BWKFTDDMBMXVHO-GXDHUFHOSA-N

物化性质

• 沸点：
  387.6±27.0 °C(Predicted)
• 密度：
  1.491±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-3-(4-bromophenyl)-2-phenylacrylic acid 在 喹啉 、 chromium(III) oxide 、 sodium hydroxide 、 苄基三乙基氯化铵 、 copper(II) oxide 作用下， 反应 50.0h， 生成
  参考文献：
  名称：

  Synthesis and biological evaluation of 1,1-Dichloro-2,3-diarylcyclopropanes as antitubulin and anti-breast cancer agents

  摘要：

  Z-1,1-Dichloro-2,3-diphenylcyclopropane (1) is an effective 'anti-breast cancer agent in rodents and in cell culture. We recently determined that 1 inhibits tubulin assembly in vitro. and causes microtubule loss in breast cancer cells, leading to accumulation in the G2/M portion of the cell cycle. Aryl ring-halogenated, methoxylated and benzyloxylated derivatives of 1, as well as its E-isomer and the dichlorocyclopropyl derivative of diethylstilbestrol (DES), were synthesized and tested for their ability to inhibit the assembly of tubulin into micro tubules. Including 1, 17 cyclopropyl compounds were tested. One (Z-1,1-dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane (12)) was found to be more active than 1. In addition, E-1,1-dichlorocyclopropylDES (17) was more potent than DES. The E-isomer of 1 (16) was inactive. The cytostatic activities of the compounds against MCF-7 and MDA-MB231 human breast cancer cells, and their abilities to perturb microtubules in MCF-7 cells were also evaluated. Z-Dichloro-2-(4-fluorophenyl)-3-phenylcyclo (5), Z-1,1-dichloro-2-(4-fluorophenyl)-3-(4-methoxyphenyl)cyclopropane (11), and Z-1,1-dichloro-2-(4-methoxyphenyl) -3-phenylcyclopropane (12) were more potent than 1 against the breast cancer cells. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00014-x
• 作为产物：
  描述：

  苯乙酸 、 对溴苯甲醛 在 乙酸酐 、 三乙胺 作用下， 生成 (E)-3-(4-bromophenyl)-2-phenylacrylic acid
  参考文献：
  名称：

  Synthesis and biological evaluation of 1,1-Dichloro-2,3-diarylcyclopropanes as antitubulin and anti-breast cancer agents

  摘要：

  Z-1,1-Dichloro-2,3-diphenylcyclopropane (1) is an effective 'anti-breast cancer agent in rodents and in cell culture. We recently determined that 1 inhibits tubulin assembly in vitro. and causes microtubule loss in breast cancer cells, leading to accumulation in the G2/M portion of the cell cycle. Aryl ring-halogenated, methoxylated and benzyloxylated derivatives of 1, as well as its E-isomer and the dichlorocyclopropyl derivative of diethylstilbestrol (DES), were synthesized and tested for their ability to inhibit the assembly of tubulin into micro tubules. Including 1, 17 cyclopropyl compounds were tested. One (Z-1,1-dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane (12)) was found to be more active than 1. In addition, E-1,1-dichlorocyclopropylDES (17) was more potent than DES. The E-isomer of 1 (16) was inactive. The cytostatic activities of the compounds against MCF-7 and MDA-MB231 human breast cancer cells, and their abilities to perturb microtubules in MCF-7 cells were also evaluated. Z-Dichloro-2-(4-fluorophenyl)-3-phenylcyclo (5), Z-1,1-dichloro-2-(4-fluorophenyl)-3-(4-methoxyphenyl)cyclopropane (11), and Z-1,1-dichloro-2-(4-methoxyphenyl) -3-phenylcyclopropane (12) were more potent than 1 against the breast cancer cells. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0968-0896(97)00014-x

文献信息

• The synergistic copper/ppm Pd-catalyzed hydrocarboxylation of alkynes with formic acid as a CO surrogate as well as a hydrogen source: an alternative indirect utilization of CO₂
  作者：Shu-Mei Xia、Zhi-Wen Yang、Xiang-Yang Yao、Kai-Hong Chen、Li-Qi Qiu、Liang-Nian He

  DOI：10.1039/d1gc02735b

  日期：——

  An unprecedented strategy has been developed involving the earth-abundant Cu-catalyzed hydrocarboxylation of alkynes with HCOOH to (E)-acrylic derivatives with high regio- and stereoselectivity via synergistic effects with ppm levels of a Pd catalyst. Both symmetrical and unsymmetrical alkynes bearing various functional groups were successfully hydrocarboxylated with HCOOH, and the modification of

  已经开发了一种前所未有的策略，涉及通过与 Pd 催化剂的 ppm 水平的协同效应，用 HCOOH 将地球上丰富的 Cu 催化的炔烃加氢羧化为具有高区域和立体选择性的( E )-丙烯酸衍生物。带有各种官能团的对称和不对称炔烃均成功地被 HCOOH 烃基化，药物分子的修饰体现了该过程的实用性。该协议采用 HCOOH 作为 CO 替代物和氢供体，具有 100% 的原子经济性，可以将其视为间接 CO 2使用的替代方法。机理研究表明 Cu/ppm Pd 协同催化机制通过烯基铜物种作为潜在的中间体，由铜氢化物活性催化物种形成，HCOOH 作为氢源。这种包含廉价 Cu 和痕量 Pd 的双金属系统提供了一种可靠且有效的加氢羧化方法，以 HCOOH 作为氢源获得工业上有用的丙烯酸衍生物，并为优化其他与 Cu-H 相关的助催化系统提供了新的线索。
• [EN] SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION<br/>[FR] THIAZOLES SUBSTITUES DESTINES AU TRAITEMENT DE L'INFLAMMATION
  申请人：G.D. SEARLE & CO.

  公开号：WO1996003392A1

  公开（公告）日：1996-02-08

  (EN) A class of substituted thiazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula (II), wherein R4 is selected from alkyl and amino, wherein R5 is selected from aryl, cycloalkyl, cycloalkenyl and heterocyclic; wherein R5 is optionally substituted at a substitutable position with one or more radicals selected from halo, alkylthio, alkylsulfinyl, alkylsulfonyl, haloalkylsulfonyl, aminosulfonyl, alkyl, alkenyl, alkynyl, cyano, carboxyl, carboxyalkyl, alkoxycarbonyl, aminocarbonyl, acyl, N-alkylaminocarbonyl, N-arylaminocarbonyl, N,N-dialkylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, haloalkyl, hydroxyl, alkoxy, hydroxyalkyl, haloalkoxy, amino, N-alkylamino, N,N-dialkylamino, heterocyclic and nitro; and wherein R6 is selected from halo, amino, alkoxy, nitro, hydroxyl, aminocarbonyl, acyl, alkylaminocarbonyl, arylaminocarbonyl, alkenyl, alkynyl, haloalkoxy, alkylamino, arylamino, aralkylamino, alkoxycarbonylalkyl, alkylaminoalkyl, heterocycloalkyl, aralkyl, cyanoalkyl, N-alkylsulfonylamino, heteroarylsulfonylalkyl, heteroarylsulfonylhaloalkyl, aryloxyalkyl, aralkyloxyalkyl, aryl and heterocyclo, wherein the aryl and heterocyclo radicals are optionally substituted at a substitutable position with one or more radicals selected from halo, alkyl, alkoxy, alkylthio, alkylsulfinyl, haloalkyl, haloalkoxy, carboxyalkyl, alkoxycarbonyl, aminocarbonyl, amino, acyl and alkylamino; or a pharmaceutically-acceptable salt thereof.(FR) La présente invention concerne une classe de composés à base de thiazolyle substitué destinés au traitement de l'inflammation et des troubles liés à l'inflammation. Les composés concernés en l'occurrence sont décrits par la formule générale (II). Dans cette formule générale, R4 est choisi parmi alkyle et amino. R5 est choisi parmi aryle, cycloalkyle, cycloalcényle et hétérocyclique. R5 est éventuellement substitué à des positions admettant la substitution par un ou plusieurs radicaux choisis parmi halo, alkylthio, alkylsulfinyle, alkylsulfonyle, haloalkylsulfonyle, aminosulfonyle, alkyle, alcényle, alkynyle, cyano, carboxyle, carboxyalkyle, alcoxycarbonyle, aminocarbonyle, acyle, N-alkylaminocarbonyle, N-arylaminocarbonyle, N,N-dialkylaminocarbonyle, N-alkyl-N-alkylaminocarbonyle, haloalkyle, hydroxyle, alcoxy, hydroxyalkyle, haloalcoxy, amino, N-alkylamino, N,N-dialkylamino, hétérocyclique et nitro. Dans cette formule générale, R6 est choisi parmi halo, amino, alcoxy, nitro, hydroxyle, aminocarbonyle, acyle, alkylaminocarbonyle, arylaminocarbonyle, alcényle, alkynyle, haloalcoxy, alkylamino, arylamino, aralkylamino, alcoxycarbonylalkyle, alkylaminoalkyle, hétérocycloalkyle, aralkyle, cyanoalkyle, N-alkysulfonylamino, hétéroarylsulfonylalkyle, hétéroarylsulfonylhaloalkyle, aryloxyalkyle, aralkyloxyalkyle, aryle et hétérocyclo, où les radicaux aryle et hétérocyclo peuvent être éventuellement substitués à une position admettant la substitution par au moins un radical choisi parmi halo, alkyle, alcoxy, alkylthio, alkylsulfinyle, haloalkyle, haloalcoxy, carboxyalkyle, alcoxycarbonyle, aminocarbonyle, amino, acyle et alkylamino. L'invention concerne également des sels de ces composés de formule générale (II), qui sont pharmaceutiquement acceptables.

  描述了一类取代噻唑基化合物，用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由公式（II）定义，其中R4选择自烷基和氨基，其中R5选择自芳基，环烷基，环烯基和杂环；其中R5在可取代的位置上可选择用一个或多个基团进行取代，所述基团选择自卤素，烷硫基，烷基亚砜基，烷基磺酰基，卤代烷基磺酰基，氨基磺酰基，烷基，烯基，炔基，氰基，羧基，羧基烷基，烷氧基羧酸酯基，氨基羧酸酯基，酰基，N-烷基氨基羧酸酯基，N-芳基氨基羧酸酯基，N，N-二烷基氨基羧酸酯基，N-烷基-N-芳基氨基羧酸酯基，卤代烷基，羟基，烷氧基，卤代烷氧基，氨基，N-烷基氨基，N，N-二烷基氨基，杂环和硝基；其中R6选择自卤素，氨基，烷氧基，硝基，羟基，氨基羧酸酯基，酰基，烷基氨基羧酸酯基，芳基氨基羧酸酯基，烯基，炔基，卤代烷氧基，烷基氨基，芳基氨基，芳基烷基氨基，烷氧基羧酸酯基烷基，烷基氨基烷基，杂环环烷基，芳基烷基，卤代基烷基磺酰氨基，杂环芳基磺酰基烷基，杂环芳基磺酰卤代烷基，芳氧基烷基，芳基烷氧基烷基，芳基和杂环，其中芳基和杂环基团在可取代的位置上可选择用一个或多个基团进行取代，所述基团选择自卤素，烷基，烷氧基，烷硫基，烷基亚砜基，卤代烷基，卤代烷氧基，羧基烷基，烷氧基羧酸酯基，氨基羧酸酯基，氨基，酰基和烷基氨基；或其药学上可接受的盐。
• Substituted thiazoles for the treatment of inflammation
  申请人：G.D. SEARLE & CO.

  公开号：EP1125932A2

  公开（公告）日：2001-08-22

  A class of substituted thiazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II wherein R4 is selected from methyl and amino; wherein R5 is selected from optionally substituted aryl, cycloalkyl, cycloalkenyl and heterocyclic; and wherein R6 is selected from hydrogen or specified substituents; or a pharmaceutically-acceptable salt thereof.

  描述了一类用于治疗炎症和炎症相关疾病的取代噻唑化合物。特别感兴趣的化合物由式 II 定义 其中 R4 选自甲基和氨基；其中 R5 选自任选取代的芳基、环烷基、环烯基和杂环基；其中 R6 选自氢或特定取代基；或其药学上可接受的盐。
• SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION
  申请人：G.D. SEARLE & CO.

  公开号：EP0772606A1

  公开（公告）日：1997-05-14